International journal of cancer research最新文献

英文中文

Chloroform Extract of Solanum trilobatum Inhibits the Progress of Ehrlich Ascites Carcinoma in Mice 三叶草氯仿提取物抑制小鼠埃利希腹水癌的进展

International journal of cancer research

Pub Date : 2016-01-01 DOI: 10.3923/IJCR.2016.17.28

H. Sini, K. Devi, K. G. Nevin

This study was initiated to evaluate the modulating effect of chloroform extract of Solanum trilobatum (CST) on Ehrlich Ascites Carcinoma (EAC) in mice. In vitro cytotoxicity of CST on Ehrlich Ascites Cells (EAC) and Human Leukemic cells (HL-60 cells) were evaluated using trypan blue staining. To study the in vivo effect of CST, tumors were introduced into experimental animals by intraperitoneal injection. Animals were treated with CST (400 mg kgG b.wt., after 24 h and 7 days of tumor inoculation for five alternate days. Cisplatin, an antitumor drug (2 mg kgG b.wt.,) was used as a positive control starting from first and the seventh day of tumor inoculation, respectively. After the experimental period, antitumor parameters (ascitic tumor volume, mean survival time and viability of tumor cells), hematological studies and biochemical parameters (activities of SGOT, SGPT, ALP and LDH) were measured. Results showed that CST strongly inhibited the growth of HL-60 and EAC cell line in in vitro condition. In in vivo conditions, administration of CST reduced the tumor volume and the viability of tumor cells as well as increased the mean survival time of EAC inoculated mice. Activities of liver enzymes were found to be restored by the administration of CST. Histopathological examination showed that CST was capable of reducing the damage caused to the liver by the excessive tumor growth. The cytotoxic and antitumor effect demonstrated by this study supported the fact that the antioxidant components present in CST may be a promising source of antitumor compounds for managing different types of cancer.

研究三叶龙脑氯仿提取物对小鼠埃利希腹水癌(EAC)的调节作用。台盼蓝染色法观察CST对埃利希腹水细胞(EAC)和人白血病细胞(HL-60细胞)的体外细胞毒性。为了研究CST在体内的作用，我们通过腹腔注射将肿瘤引入实验动物。动物用CST (400 mg kgG b.wt)治疗。，接种24 h和7 d后，交替5天。阳性对照采用抗肿瘤药物顺铂(2 mg kgG b.wt.，)，分别从肿瘤接种第1天和第7天开始。实验结束后，测定抗肿瘤指标(腹水肿瘤体积、肿瘤细胞平均存活时间和活力)、血液学指标和生化指标(SGOT、SGPT、ALP和LDH活性)。结果表明，在体外条件下，CST对HL-60和EAC细胞株的生长有较强的抑制作用。在体内条件下，CST降低了EAC接种小鼠的肿瘤体积和肿瘤细胞的活力，并增加了平均存活时间。肝酶活性被发现在服用CST后恢复。组织病理学检查显示，CST能减轻肿瘤过度生长对肝脏的损害。本研究显示的细胞毒性和抗肿瘤作用支持了这样一个事实，即CST中的抗氧化成分可能是治疗不同类型癌症的抗肿瘤化合物的有希望的来源。

{"title":"Chloroform Extract of Solanum trilobatum Inhibits the Progress of Ehrlich Ascites Carcinoma in Mice","authors":"H. Sini, K. Devi, K. G. Nevin","doi":"10.3923/IJCR.2016.17.28","DOIUrl":"https://doi.org/10.3923/IJCR.2016.17.28","url":null,"abstract":"This study was initiated to evaluate the modulating effect of chloroform extract of Solanum trilobatum (CST) on Ehrlich Ascites Carcinoma (EAC) in mice. In vitro cytotoxicity of CST on Ehrlich Ascites Cells (EAC) and Human Leukemic cells (HL-60 cells) were evaluated using trypan blue staining. To study the in vivo effect of CST, tumors were introduced into experimental animals by intraperitoneal injection. Animals were treated with CST (400 mg kgG b.wt., after 24 h and 7 days of tumor inoculation for five alternate days. Cisplatin, an antitumor drug (2 mg kgG b.wt.,) was used as a positive control starting from first and the seventh day of tumor inoculation, respectively. After the experimental period, antitumor parameters (ascitic tumor volume, mean survival time and viability of tumor cells), hematological studies and biochemical parameters (activities of SGOT, SGPT, ALP and LDH) were measured. Results showed that CST strongly inhibited the growth of HL-60 and EAC cell line in in vitro condition. In in vivo conditions, administration of CST reduced the tumor volume and the viability of tumor cells as well as increased the mean survival time of EAC inoculated mice. Activities of liver enzymes were found to be restored by the administration of CST. Histopathological examination showed that CST was capable of reducing the damage caused to the liver by the excessive tumor growth. The cytotoxic and antitumor effect demonstrated by this study supported the fact that the antioxidant components present in CST may be a promising source of antitumor compounds for managing different types of cancer.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"663 1","pages":"17-28"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77028898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma. 靶向骨髓增强酪氨酸激酶抑制剂在人胶质母细胞瘤大鼠临床前模型中的抗肿瘤作用。

International journal of cancer research

Pub Date : 2016-01-01 Epub Date: 2016-03-15 DOI: 10.3923/ijcr.2016.69.81

S Shaaban, M Alsulami, S A Arbab, R Ara, A Shankar, A Iskander, K Angara, M Jain, H Bagher-Ebadian, B R Achyut, A S Arbab

Antiangiogenic agents caused paradoxical increase in pro-growth and pro-angiogenic factors and caused tumor growth in glioblastoma (GBM). It is hypothesized that paradoxical increase in pro-angiogenic factors would mobilize Bone Marrow Derived Cells (BMDCs) to the treated tumor and cause refractory tumor growth. The purposes of the studies were to determine whether whole body irradiation (WBIR) or a CXCR4 antagonist (AMD3100) will potentiate the effect of vatalanib (a VEGFR2 tyrosine kinase inhibitor) and prevent the refractory growth of GBM. Human GBM were grown orthotopically in three groups of rats (control, pretreated with WBIR and AMD3100) and randomly selected for vehicle or vatalanib treatments for 2 weeks. Then all animals underwent Magnetic Resonance Imaging (MRI) followed by euthanasia and histochemical analysis. Tumor volume and different vascular parameters (plasma volume (v_p), forward transfer constant (K^trans), back flow constant (k_ep), extravascular extracellular space volume (v_e) were determined from MRI. In control group, vatalanib treatment increased the tumor growth significantly compared to that of vehicle treatment but by preventing the mobilization of BMDCs and interaction of CXCR4-SDF-1 using WBIR and ADM3100, respectively, paradoxical growth of tumor was controlled. Pretreatment with WBIR or AMD3100 also decreased tumor cell migration, despite the fact that ADM3100 increased the accumulation of M1 and M2 macrophages in the tumors. Vatalanib also increased K^trans and v_e in control animals but both of the vascular parameters were decreased when the animals were pretreated with WBIR and AMD3100. In conclusion, depleting bone marrow cells or CXCR4 interaction can potentiate the effect of vatalanib.

抗血管生成药物引起促生长因子和促血管生成因子的矛盾增加，并引起胶质母细胞瘤(GBM)的肿瘤生长。据推测，促血管生成因子的矛盾增加将调动骨髓衍生细胞(bmdc)到治疗的肿瘤，并导致难治性肿瘤生长。这些研究的目的是确定全身照射(WBIR)或CXCR4拮抗剂(AMD3100)是否会增强vatalanib(一种VEGFR2酪氨酸激酶抑制剂)的作用并防止GBM的难治性生长。人类GBM在三组大鼠(对照组，WBIR和AMD3100预处理)中原位生长，并随机选择进行对照或vatalanib治疗2周。然后对所有动物进行核磁共振成像(MRI)，然后进行安乐死和组织化学分析。MRI测定肿瘤体积及各血管参数(血浆体积(vp)、前向转移常数(Ktrans)、回流常数(keep)、血管外细胞间隙体积(ve))。在对照组中，vatalanib治疗与载体治疗相比，肿瘤生长明显增加，但通过分别阻止BMDCs的动员和CXCR4-SDF-1与WBIR和ADM3100的相互作用，肿瘤的矛盾生长得到了控制。尽管ADM3100增加了肿瘤中M1和M2巨噬细胞的积累，但WBIR或AMD3100预处理也降低了肿瘤细胞的迁移。Vatalanib在对照动物中也增加了Ktrans和ve，但在用WBIR和AMD3100预处理动物时，这两个血管参数都降低了。总之，消耗骨髓细胞或CXCR4相互作用可增强vatalanib的作用。

{"title":"Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.","authors":"S Shaaban, M Alsulami, S A Arbab, R Ara, A Shankar, A Iskander, K Angara, M Jain, H Bagher-Ebadian, B R Achyut, A S Arbab","doi":"10.3923/ijcr.2016.69.81","DOIUrl":"https://doi.org/10.3923/ijcr.2016.69.81","url":null,"abstract":"Antiangiogenic agents caused paradoxical increase in pro-growth and pro-angiogenic factors and caused tumor growth in glioblastoma (GBM). It is hypothesized that paradoxical increase in pro-angiogenic factors would mobilize Bone Marrow Derived Cells (BMDCs) to the treated tumor and cause refractory tumor growth. The purposes of the studies were to determine whether whole body irradiation (WBIR) or a CXCR4 antagonist (AMD3100) will potentiate the effect of vatalanib (a VEGFR2 tyrosine kinase inhibitor) and prevent the refractory growth of GBM. Human GBM were grown orthotopically in three groups of rats (control, pretreated with WBIR and AMD3100) and randomly selected for vehicle or vatalanib treatments for 2 weeks. Then all animals underwent Magnetic Resonance Imaging (MRI) followed by euthanasia and histochemical analysis. Tumor volume and different vascular parameters (plasma volume (vp), forward transfer constant (Ktrans), back flow constant (kep), extravascular extracellular space volume (ve) were determined from MRI. In control group, vatalanib treatment increased the tumor growth significantly compared to that of vehicle treatment but by preventing the mobilization of BMDCs and interaction of CXCR4-SDF-1 using WBIR and ADM3100, respectively, paradoxical growth of tumor was controlled. Pretreatment with WBIR or AMD3100 also decreased tumor cell migration, despite the fact that ADM3100 increased the accumulation of M1 and M2 macrophages in the tumors. Vatalanib also increased Ktrans and ve in control animals but both of the vascular parameters were decreased when the animals were pretreated with WBIR and AMD3100. In conclusion, depleting bone marrow cells or CXCR4 interaction can potentiate the effect of vatalanib.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"12 2","pages":"69-81"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945124/pdf/nihms749728.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34569464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Chemopreventive Potential of Sunflower Seeds in a Human Colon Cancer Cell Line 葵花籽对人结肠癌细胞系的化学预防作用

International journal of cancer research

Pub Date : 2016-01-01 DOI: 10.3923/IJCR.2016.40.50

L. Smith, J. Patterson, L. Walker, M. Verghese

Sunflower Seed (SS) (Helianthus annuus L.) is an oil seed crop that is a good source of protein. The objective of this study was to investigate the chemopreventive potential of SS extracts (defatted and whole) through determination of phytochemical content, antioxidative potential and cytotoxic effects on Caco-2 cells. Phytochemical (total phenolic, total flavonoid) content, Trolox Equivalent Antioxidant Capacity (TEAC), free radical-scavenging ability of 2, 2-diphenyl-1-picrylhydrazyl (DPPH) and Ferric Reducing Antioxidant Potential (FRAP) were determined according to standard protocol. Lactate dehydrogenase (LDH) release (cytotoxicity assay) was used to measure in vitro cell damage of Caco-2 colon cancer cells. Activity of cellular detoxification and antioxidant enzymes was determined with selected concentrations of SS extracts (25, 50 and 100 μg mLG). Apoptotic activity was assessed through the activity of Caspase-3 and DNA fragmentation ELISA. Anti-inflammatory activity was assessed through Cox-2. Total phenolic content was 62.76±7.37 mg GAE/100 g and total flavonoid content of SS extracts was 26.49 mg CE/100 g. Antioxidant potential: TEAC was 858.83±97.7 μmol TE/100 g, DPPH radical scavenging (IC50 value) was 8 mg mLG 1 and FRAP was 14.13±1.25 mmol/Fe/g for SS extracts. The LDH release (%), cytotoxicity, after 12 and 24 h incubation with SS extracts was 39.8 and 53.1% at 25 μg mLG. Caspase-3 activity was 18.60±0.19, Cox-2 was 0.28 U mLG and DNA fragmentation ELISA was 0.47 EF at 24 h incubation of extract at 100 μg mLG. The results for the antioxidant and detoxification enzymes yielded were: GST (0.0017±0.001 nmol minG mLG), CAT 24.1±0.13 U mgG, GPx 30.4±0 nmol minG mLG, SOD 313.3±3.98 U mLG and GSH 13.7± nmol mLG. Results of this study revealed high phenolic and flavonoid content and suggested cytotoxic and antioxidative potential of SS extracts as a chemopreventive agent.

葵花籽(SS) (Helianthus annuus L.)是一种富含蛋白质的油籽作物。本研究的目的是通过测定SS提取物(脱脂提取物和全提取物)的植物化学成分、抗氧化潜能和对Caco-2细胞的细胞毒作用，探讨SS提取物(脱脂提取物和全提取物)的化学预防潜力。按标准方案测定植物化学(总酚、总黄酮)含量、Trolox等效抗氧化能力(TEAC)、2,2 -二苯基-1- picryhydrazyl (DPPH)自由基清除能力和铁还原抗氧化电位(FRAP)。采用乳酸脱氢酶(LDH)释放(细胞毒性测定)法测定Caco-2结肠癌细胞的体外细胞损伤。选取浓度为25、50和100 μg mLG的SS提取物，测定其细胞解毒和抗氧化酶活性。通过Caspase-3活性和DNA片段化ELISA检测细胞凋亡活性。通过Cox-2评估抗炎活性。总酚含量为62.76±7.37 mg CE/100 g，总黄酮含量为26.49 mg CE/100 g。抗氧化能力:TEAC为858.83±97.7 μmol TE/100 g, DPPH自由基清除率(IC50值)为8 mg mLG 1, FRAP为14.13±1.25 mmol/Fe/g。在25 μg mLG下，SS提取物作用12 h和24 h后LDH的细胞毒性释放率分别为39.8%和53.1%。100 μg mLG提取液孵育24 h时，Caspase-3活性为18.60±0.19,Cox-2活性为0.28 U mLG, DNA片段酶联免疫吸附试验(ELISA)为0.47 EF。所得抗氧化和解毒酶分别为:GST(0.0017±0.001 nmol)、CAT(24.1±0.13)、GPx(30.4±0 nmol)、SOD(313.3±3.98)、GSH(13.7±nmol)。研究结果表明，SS提取物具有较高的酚类和类黄酮含量，具有细胞毒性和抗氧化潜力，可作为化学预防剂。

{"title":"Chemopreventive Potential of Sunflower Seeds in a Human Colon Cancer Cell Line","authors":"L. Smith, J. Patterson, L. Walker, M. Verghese","doi":"10.3923/IJCR.2016.40.50","DOIUrl":"https://doi.org/10.3923/IJCR.2016.40.50","url":null,"abstract":"Sunflower Seed (SS) (Helianthus annuus L.) is an oil seed crop that is a good source of protein. The objective of this study was to investigate the chemopreventive potential of SS extracts (defatted and whole) through determination of phytochemical content, antioxidative potential and cytotoxic effects on Caco-2 cells. Phytochemical (total phenolic, total flavonoid) content, Trolox Equivalent Antioxidant Capacity (TEAC), free radical-scavenging ability of 2, 2-diphenyl-1-picrylhydrazyl (DPPH) and Ferric Reducing Antioxidant Potential (FRAP) were determined according to standard protocol. Lactate dehydrogenase (LDH) release (cytotoxicity assay) was used to measure in vitro cell damage of Caco-2 colon cancer cells. Activity of cellular detoxification and antioxidant enzymes was determined with selected concentrations of SS extracts (25, 50 and 100 μg mLG). Apoptotic activity was assessed through the activity of Caspase-3 and DNA fragmentation ELISA. Anti-inflammatory activity was assessed through Cox-2. Total phenolic content was 62.76±7.37 mg GAE/100 g and total flavonoid content of SS extracts was 26.49 mg CE/100 g. Antioxidant potential: TEAC was 858.83±97.7 μmol TE/100 g, DPPH radical scavenging (IC50 value) was 8 mg mLG 1 and FRAP was 14.13±1.25 mmol/Fe/g for SS extracts. The LDH release (%), cytotoxicity, after 12 and 24 h incubation with SS extracts was 39.8 and 53.1% at 25 μg mLG. Caspase-3 activity was 18.60±0.19, Cox-2 was 0.28 U mLG and DNA fragmentation ELISA was 0.47 EF at 24 h incubation of extract at 100 μg mLG. The results for the antioxidant and detoxification enzymes yielded were: GST (0.0017±0.001 nmol minG mLG), CAT 24.1±0.13 U mgG, GPx 30.4±0 nmol minG mLG, SOD 313.3±3.98 U mLG and GSH 13.7± nmol mLG. Results of this study revealed high phenolic and flavonoid content and suggested cytotoxic and antioxidative potential of SS extracts as a chemopreventive agent.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"20 1","pages":"40-50"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87388140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Risk Factors for Epithelial Ovarian Carcinoma in India: A Case Control Study in Low-Incidence Population 印度上皮性卵巢癌的危险因素:低发病率人群的病例对照研究

International journal of cancer research

Pub Date : 2016-01-01 DOI: 10.3923/IJCR.2016.61.68

S. Shanmughap, G. Senthilkum, S. Arun, B. Das, K. Natarajase

引用次数: 9

Cytotoxic and Apoptotic Effects of Sprouted and Non-sprouted Lentil, Green and Yellow Split-peas 发芽和未发芽小扁豆、绿豌豆和黄豌豆的细胞毒性和凋亡效应

International journal of cancer research

Pub Date : 2016-01-01 DOI: 10.3923/IJCR.2016.51.60

K. Busambwa, R. Sunkara, N. Diby, R. O. Okyne, J. Boateng, M. Verghese

引用次数: 12

Clinical Implications of Microarray in Cancer Medicine 微阵列在癌症医学中的临床意义

International journal of cancer research

Pub Date : 2015-04-01 DOI: 10.3923/IJCR.2015.150.158

J. Kang

Cancers are associated with an array of orchestrated genetic changes and the identification of changes causally related to the carcinogenic process. To elucidate the mechanism of cancer carcinogenesis, it is necessary to reconstruct molecular events at each level. Microarray technology is a versatile platform that allows rapid genetic analysis to take place on a genome-wide scale and has revolutionized to evaluate genetic markers and changes in cancer genetics. Since, their development in the mid-1990s, these technologies have become a key tool in the fight against cancer. Microarray data have led to the identification of molecular subclasses of solid tumors characterized by distinct oncogenic pathways, as well as the development of multigene prognostic or predictive models equivalent or superior to those of established clinical parameters. Currently, several genomic aberrations discovered by these assays are presently being used as predictive markers for cancer treatment with targeted therapeutics. But how do microarrays work and just how have they been used in cancer diagnosis and treatment thus far? Here, we presented a summary of the main applications of microarrays in the field of targeted therapies of cancer and discussed their potential in clinical implementation.

癌症与一系列精心安排的遗传变化以及与致癌过程有因果关系的变化的识别有关。为了阐明癌症的癌变机制，有必要在各个水平上重建分子事件。微阵列技术是一个多功能平台，允许在全基因组范围内进行快速遗传分析，并彻底改变了评估遗传标记和癌症遗传学的变化。自20世纪90年代中期发展以来，这些技术已成为对抗癌症的关键工具。微阵列数据已经导致实体肿瘤分子亚类的鉴定，其特征是不同的致癌途径，以及多基因预后或预测模型的发展相当于或优于那些已建立的临床参数。目前，通过这些检测发现的一些基因组畸变目前被用作靶向治疗癌症治疗的预测标记。但是到目前为止，微阵列是如何工作的，它们在癌症诊断和治疗中的应用又是如何的呢?本文综述了微阵列技术在癌症靶向治疗领域的主要应用，并讨论了其在临床应用中的潜力。

{"title":"Clinical Implications of Microarray in Cancer Medicine","authors":"J. Kang","doi":"10.3923/IJCR.2015.150.158","DOIUrl":"https://doi.org/10.3923/IJCR.2015.150.158","url":null,"abstract":"Cancers are associated with an array of orchestrated genetic changes and the identification of changes causally related to the carcinogenic process. To elucidate the mechanism of cancer carcinogenesis, it is necessary to reconstruct molecular events at each level. Microarray technology is a versatile platform that allows rapid genetic analysis to take place on a genome-wide scale and has revolutionized to evaluate genetic markers and changes in cancer genetics. Since, their development in the mid-1990s, these technologies have become a key tool in the fight against cancer. Microarray data have led to the identification of molecular subclasses of solid tumors characterized by distinct oncogenic pathways, as well as the development of multigene prognostic or predictive models equivalent or superior to those of established clinical parameters. Currently, several genomic aberrations discovered by these assays are presently being used as predictive markers for cancer treatment with targeted therapeutics. But how do microarrays work and just how have they been used in cancer diagnosis and treatment thus far? Here, we presented a summary of the main applications of microarrays in the field of targeted therapies of cancer and discussed their potential in clinical implementation.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"54 1","pages":"150-158"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85210842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Tumoricidal Property of Normoxia and Hypoxia Cell-Free Lysate ofWharton’s Jelly-Mesenchymal Stem Cells Toward Various CancerCells 常氧和缺氧无细胞的wharton’s Jelly-Mesenchymal干细胞裂解液对多种癌细胞的杀瘤特性

International journal of cancer research

Pub Date : 2015-04-01 DOI: 10.3923/IJCR.2015.186.196

W. Widowati, L. Wijaya, D. Agustina, Harry Murti, N. Fauziah, S. Sumitro, M. Widodo, I. Bachtiar

Cancer is one of the leading causes of mortality and morbidity throughout the world. Since there are still some problems related to the conventional therapies for cancer treatment, it is critical to explore new more efficient therapy strategies. Mesenchymal Stem Cells (MSCs) are one of powerful tools for tissue engineering for regenerative medicine, as recent research aims to utilize MSCs for anti-cancer treatment. Our previous research demonstrated that Conditioned Medium from Whartons’ Jelly MSCs (WJ-MSCs-CM) significantly lowered cancer proliferation of various cancer cell lines. This research was performed to evaluate the tumoricidal property of cell lysate from WJ-MSCs from normoxia (WJMSCs-norCL) and hypoxia-treated WJMSCs (WJMSCs-hypoCL) on the proliferation of human cancer cells, including cervical (HeLa), liver (HepG2), ovarian (SKOV3) and oral squamous (HSC3) cancer cell lines compared to normal cells including mouse fibroblast (NIH3T3), human Mesenchymal Stem Cells (hMSCs), human fibroblast. The WJMSCs-norCL and WJMSCs-hypoCL have cytotoxic activity, reduce proliferation of various cancer cell lines with minimum inhibitory concentration (IC50) 21.094-95.928 μg mLG1 and no cytotoxic to normal cells with IC50 409, 191-629, 799.738 μg mLG1. The WJMSCs-norCL and WJMSCs-hypoCL inhibit proliferation in various cancer cell lines and are not toxic for normal cells.

癌症是全世界死亡和发病的主要原因之一。由于传统的癌症治疗方法仍然存在一些问题，探索新的更有效的治疗策略是至关重要的。间充质干细胞(Mesenchymal Stem Cells, MSCs)是再生医学组织工程的有力工具之一，近年来的研究旨在利用间充质干细胞进行抗癌治疗。我们之前的研究表明，wharton’s Jelly MSCs的条件培养基(WJ-MSCs-CM)显著降低了各种癌细胞系的肿瘤增殖。本研究评估了常氧WJ-MSCs (WJMSCs- norcl)和缺氧处理的WJMSCs (WJMSCs- hypocl)细胞裂解液对人宫颈癌(HeLa)、肝癌(HepG2)、卵巢(SKOV3)和口腔鳞癌(HSC3)癌细胞增殖的杀伤作用，并将其与正常细胞(小鼠成纤维细胞(NIH3T3)、人间充质干细胞(hMSCs)、人成纤维细胞)进行比较。WJMSCs-norCL和WJMSCs-hypoCL具有细胞毒活性，可抑制多种癌细胞的增殖，最低抑制浓度(IC50)为21.094 ~ 95.928 μg mLG1，对正常细胞无细胞毒作用，IC50分别为409、191 ~ 629、799.738 μg mLG1。WJMSCs-norCL和WJMSCs-hypoCL抑制多种癌细胞系的增殖，对正常细胞无毒。

{"title":"Tumoricidal Property of Normoxia and Hypoxia Cell-Free Lysate ofWharton’s Jelly-Mesenchymal Stem Cells Toward Various CancerCells","authors":"W. Widowati, L. Wijaya, D. Agustina, Harry Murti, N. Fauziah, S. Sumitro, M. Widodo, I. Bachtiar","doi":"10.3923/IJCR.2015.186.196","DOIUrl":"https://doi.org/10.3923/IJCR.2015.186.196","url":null,"abstract":"Cancer is one of the leading causes of mortality and morbidity throughout the world. Since \u0000there are still some problems related to the conventional therapies for cancer treatment, it is \u0000critical to explore new more efficient therapy strategies. Mesenchymal Stem Cells (MSCs) are one \u0000of powerful tools for tissue engineering for regenerative medicine, as recent research aims to utilize \u0000MSCs for anti-cancer treatment. Our previous research demonstrated that Conditioned Medium \u0000from Whartons’ Jelly MSCs (WJ-MSCs-CM) significantly lowered cancer proliferation of various \u0000cancer cell lines. This research was performed to evaluate the tumoricidal property of cell lysate \u0000from WJ-MSCs from normoxia (WJMSCs-norCL) and hypoxia-treated WJMSCs (WJMSCs-hypoCL) \u0000on the proliferation of human cancer cells, including cervical (HeLa), liver (HepG2), ovarian \u0000(SKOV3) and oral squamous (HSC3) cancer cell lines compared to normal cells including \u0000mouse fibroblast (NIH3T3), human Mesenchymal Stem Cells (hMSCs), human fibroblast. The \u0000WJMSCs-norCL and WJMSCs-hypoCL have cytotoxic activity, reduce proliferation of various \u0000cancer cell lines with minimum inhibitory concentration (IC50) 21.094-95.928 μg mLG1 and no \u0000cytotoxic to normal cells with IC50 409, 191-629, 799.738 μg mLG1. The WJMSCs-norCL and \u0000WJMSCs-hypoCL inhibit proliferation in various cancer cell lines and are not toxic for normal cells.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"16 1","pages":"186-196"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84348537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic Myeloid Leukemia in Patient with Local Recurrence Colon Cancer: A Case Report 慢性髓系白血病合并局部复发结肠癌1例报告

International journal of cancer research

Pub Date : 2015-04-01 DOI: 10.3923/IJCR.2015.197.200

M. Payandeh, Edris Sadeghi, M. Sadeghi, F. Falsafi, S. Madani

Chronic Myeloid Leukemia (CML) is a chronic disease that about 50% of patients are more than 60 years old and about 50% of patients are asymptomatic. In this study, It is reported that, a case of CML after colon cancer chemotherapy in a 52 year old male from Iran who diagnosed locally advanced poorly differentiation colon adenocarcinoma with extension to prostate for him that had undergone to chemotherapy induction, then chemoradiation with surgery for mid-rectal cancer in the follow-up with picture of local recurrence and rectovesical-fistula. His first regimen in induction chemotherapy phase been oxaliplatin plus capecitabine and follow with chemoradiation for one month. The KRAS was mutation for the patient. He treated with combination of capecitabine with bevacizumab. After new progression he treated with Xeloda+irinotecan regimen. In routine follow-up in complete blood count analysis, It was found that shift to left with immature granulocytopoietic forms. Analysis by RT-PCR peripheral blood showed that Philadelphia chromosome was positive, so CML was diagnosed for him and was add imatinib to his treatment policy. Combination of oxaliplatin and irinotecan can be carcinogenic even they can probably create secondary hematological malignancy like CML and also irradiation can be other risk factor in patients with colorectal cancer following chemotherapy.

慢性髓系白血病(Chronic Myeloid Leukemia, CML)是一种慢性疾病，约50%的患者年龄在60岁以上，约50%的患者无症状。本研究报告1例来自伊朗的52岁男性，结肠癌化疗后发生CML，经化疗诱导后行局部晚期低分化结肠腺癌并延伸至前列腺，术后行中直肠癌放化疗合并手术，局部复发，直肠膀胱瘘。诱导化疗阶段的首个方案为奥沙利铂加卡培他滨，随后化疗一个月。KRAS对患者来说是突变的。他使用卡培他滨联合贝伐单抗治疗。新进展后给予希罗达+伊立替康方案治疗。在常规随访全血细胞计数分析中，发现左移伴不成熟的粒细胞生成形式。RT-PCR分析外周血Philadelphia染色体阳性，诊断为CML，给予伊马替尼治疗。奥沙利铂和伊立替康的联合使用可能致癌甚至可能造成继发性血液恶性肿瘤，如慢性粒细胞白血病同时，放疗也可能是化疗后结肠直肠癌患者的另一个风险因素。

{"title":"Chronic Myeloid Leukemia in Patient with Local Recurrence Colon Cancer: A Case Report","authors":"M. Payandeh, Edris Sadeghi, M. Sadeghi, F. Falsafi, S. Madani","doi":"10.3923/IJCR.2015.197.200","DOIUrl":"https://doi.org/10.3923/IJCR.2015.197.200","url":null,"abstract":"Chronic Myeloid Leukemia (CML) is a chronic disease that about 50% of patients are more than 60 years old and about 50% of patients are asymptomatic. In this study, It is reported that, a case of CML after colon cancer chemotherapy in a 52 year old male from Iran who diagnosed locally advanced poorly differentiation colon adenocarcinoma with extension to prostate for him that had undergone to chemotherapy induction, then chemoradiation with surgery for mid-rectal cancer in the follow-up with picture of local recurrence and rectovesical-fistula. His first regimen in induction chemotherapy phase been oxaliplatin plus capecitabine and follow with chemoradiation for one month. The KRAS was mutation for the patient. He treated with combination of capecitabine with bevacizumab. After new progression he treated with Xeloda+irinotecan regimen. In routine follow-up in complete blood count analysis, It was found that shift to left with immature granulocytopoietic forms. Analysis by RT-PCR peripheral blood showed that Philadelphia chromosome was positive, so CML was diagnosed for him and was add imatinib to his treatment policy. Combination of oxaliplatin and irinotecan can be carcinogenic even they can probably create secondary hematological malignancy like CML and also irradiation can be other risk factor in patients with colorectal cancer following chemotherapy.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"14 1","pages":"197-200"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80393237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cervical Cancer: A Perspective on Recent Patents 子宫颈癌:近期专利展望

International journal of cancer research

Pub Date : 2015-04-01 DOI: 10.3923/IJCR.2015.159.163

L. J. Tharappel, Parmi Patel, Ginpreet Kaur, V. Addepalli

引用次数: 1

Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125 人附睾蛋白4 (HE4) mRNA作为卵巢肿瘤预后标志物与RMI和CA125的关系

International journal of cancer research

Pub Date : 2015-04-01 DOI: 10.3923/IJCR.2015.175.185

M. Yehia, A. Mansour, S. Mekawy

Human Epididymis protein 4 (HE4) has recently been shown to improve the sensitivity and specificity of Epithelial Ovarian Cancer (EOC) diagnosis but its function in cancer cells is not clear. We evaluated HE4 expression, RMI and CA125 serum level as diagnostic tools of primary ovarian cancer in Egyptian women. The HE4 gene expression was evaluated by real time PCR in ovarian cancer of 50 Egyptian women. Ovarian cancer tissues were studied for the detection of the gene expression of HE4 by Quantitative Real Time PCR (Q RT-PCR). Serum Human cancer antigen 125 (CA 125) was measured in the serum of all participants of the study using immune sorbent assay (ELISA). The HE4 showed significant difference among ovarian malignant tumors patients compared to the control subjects (p<0.01). The best cutoff value 0.053 at which HE4 sensitivity was 92% and specificity was 96%. There was a significance correlation between HE4, RMI and CA125 in all patients of the study (p#0.01 for both). The mRNA expression of HE4 was significantly high versus the control group in early stages and low grades of the disease (p = 0.00, 0.01, respectively). As well as, there was Increased HE4 expression in the late stages of the disease suggesting that it may be associated with poor prognosis as well. The HE4 could be considered as a good prognostic marker for ovarian cancer that increases the sensitivity of the CA 125 to absolute value without affection of CA125 accuracy and its positive predictive value.

人类附睾蛋白4 (HE4)最近被证明可以提高上皮性卵巢癌(EOC)诊断的敏感性和特异性，但其在癌细胞中的功能尚不清楚。我们评估了HE4表达、RMI和CA125血清水平作为埃及妇女原发性卵巢癌的诊断工具。采用实时荧光定量PCR技术对50例埃及女性卵巢癌患者的HE4基因表达进行了检测。采用实时荧光定量PCR (qrt -PCR)检测卵巢癌组织中HE4基因的表达。采用免疫吸附试验(ELISA)测定所有受试者血清中的人癌抗原125 (CA 125)。卵巢恶性肿瘤患者HE4水平与对照组比较，差异有统计学意义(p<0.01)。最佳临界值为0.053时，HE4敏感性为92%，特异性为96%。所有患者的HE4、RMI和CA125均有显著相关性(p#0.01)。HE4 mRNA的表达在疾病早期和低分级时均明显高于对照组(p = 0.00, 0.01)。此外，HE4在疾病晚期表达升高，提示其也可能与预后不良有关。在不影响CA125准确性及其阳性预测值的情况下，HE4可提高CA125对绝对值的敏感性，可作为卵巢癌的良好预后指标。

{"title":"Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125","authors":"M. Yehia, A. Mansour, S. Mekawy","doi":"10.3923/IJCR.2015.175.185","DOIUrl":"https://doi.org/10.3923/IJCR.2015.175.185","url":null,"abstract":"Human Epididymis protein 4 (HE4) has recently been shown to improve the sensitivity and specificity of Epithelial Ovarian Cancer (EOC) diagnosis but its function in cancer cells is not clear. We evaluated HE4 expression, RMI and CA125 serum level as diagnostic tools of primary ovarian cancer in Egyptian women. The HE4 gene expression was evaluated by real time PCR in ovarian cancer of 50 Egyptian women. Ovarian cancer tissues were studied for the detection of the gene expression of HE4 by Quantitative Real Time PCR (Q RT-PCR). Serum Human cancer antigen 125 (CA 125) was measured in the serum of all participants of the study using immune sorbent assay (ELISA). The HE4 showed significant difference among ovarian malignant tumors patients compared to the control subjects (p<0.01). The best cutoff value 0.053 at which HE4 sensitivity was 92% and specificity was 96%. There was a significance correlation between HE4, RMI and CA125 in all patients of the study (p#0.01 for both). The mRNA expression of HE4 was significantly high versus the control group in early stages and low grades of the disease (p = 0.00, 0.01, respectively). As well as, there was Increased HE4 expression in the late stages of the disease suggesting that it may be associated with poor prognosis as well. The HE4 could be considered as a good prognostic marker for ovarian cancer that increases the sensitivity of the CA 125 to absolute value without affection of CA125 accuracy and its positive predictive value.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"126 1","pages":"175-185"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80382304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

International journal of cancer research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀